A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccine
Rebecca Jane Cox(Haukeland University Hospital), Lars R. Haaheim(University of Bergen), Haakon Sjursen(Haukeland University Hospital), Katja Höschler(National Security Agency), Isabella Donatelli(Istituto Superiore di Sanità), William Barclay(Imperial Valley College), Mélanie Saville(Sanofi (France)), Maria Zambon(Public Health England), Abdullah S. Madhun(Norwegian Institute of Marine Research), Mirjam Kühne, John Wood(Women's and Children's Hospital), Solveig Hauge(University of Bergen), Diane Major(National Institute for Biological Standards and Control), Frederick R. Vogel(Sanofi (France))
Cited by 140
Related Papers
Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group
|Journal of Virology|2013|1.3k
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome
|The Lancet|2003|1.1k
The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets
|Nature Microbiology|2021|802
The origins of SARS-CoV-2: A critical review
|Cell|2021|511
Invariant NKT cells reduce the immunosuppressive activity of influenza A virus–induced myeloid-derived suppressor cells in mice and humans
|Journal of Clinical Investigation|2008|349